Back to journals
Academic JournalOpen Access

Neuroscience Applied

6 Papers Indexed in Blossom

Published Papers

Open Accessmeta

A review of psychedelics trials completed in depression, informed by European regulatory perspectives

This systematic review (s=8) analyses completed controlled trials of psychedelics for depression, including psilocybin, LSD, ayahuasca, and DMT, all in Phase II or I/II. It evaluates methodological patterns against the draft European Medicines Agency guideline revision, highlighting challenges such as unblinding, expectancy, and adverse event characterisation, while calling for larger studies to assess long-term efficacy and safety.

Published
Journal
Neuroscience Applied
Authors
Silva, F., Butlen-Ducuing, F., Guizzaro, L., Balabanov, P., Meyer-Lindenberg, A.
Open Accessindividual

An investigation of acute Physiological and Psychological Moderators of Psychedelic-induced Personality Change among Healthy Volunteers

This re-analysis of a single-blind, fixed-order trial (n=28) investigates the effects of a single high-dose psilocybin (25 mg) on personality traits in psychedelic-naïve healthy volunteers. It finds significant reductions in neuroticism one month post-administration, moderated by subjective experience meaningfulness and ego dissolution, suggesting psilocybin catalyses lasting personality changes with therapeutic potential.

Published
Journal
Neuroscience Applied
Authors
Godfrey, K., Weiss, B., Zhang, X., Spriggs, M. J., Peill, J. M., Lyons, T., Carhart-Harris, R. L., Erritzoe, D.
Open Accessmeta

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

This review (2025) of the Swiss limited access scheme describes how approximately 100 physicians treated 723 patients with MDMA, LSD, or psilocybin in 2024, with patients typically receiving 2-4 psychedelic-assisted therapy sessions within 12 months for treatment-resistant conditions.

Published
Journal
Neuroscience Applied
Authors
Mueller, F., Hawrot, T., Schmid, Y.
Open Accessindividual

Safety pharmacology of acute psilocybin administration in healthy participants

This pooled analysis (n=85; doses=113) of three randomised crossover studies evaluates the safety pharmacology of psilocybin (15-30mg). Psilocybin induced stronger effects at higher doses, with 25 mg and 30 mg doses showing increased anxiety. However, overall, psilocybin was found to be safe in terms of acute psychological and physical harm, with no serious adverse reactions reported, suggesting its potential safety for controlled research settings.

Published
Journal
Neuroscience Applied
Authors
Straumann, I., Holze, F., Becker, A. M., Ley, L., Halter, N., Liechti, M. E.
Open Accessindividual

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design

This paper (2022) details the rationale and study design for an upcoming double-blind placebo-controlled trial (n=144) which will assess the safety and efficacy of using psilocybin in a cohort with treatment-resistant depression.

Published
Journal
Neuroscience Applied
Authors
Mertens, L. J., Koslowski, M., Betzler, F., Evens, R., Gilles, M., Jungaberle, A., Jungaberle, H., Maji, T., Str€ Ohle, A., Wolff, M., Wellek, S., Gründer, G.
Open Accessindividual

Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study

This prospective survey study (n=247) finds that those who microdose psychedelics to manage ADHD symptoms experience benefits from it. Participants scored higher on well-being after two and four weeks. The study design, a prospective survey, makes it possible to draw causal inferences (microdosing causing the improvement), but the study had a large drop-out rate (n=46 at 4 weeks).

Published
Journal
Neuroscience Applied
Authors
Haijen, E., Hurks, P. P. M., Kuypers, K. P. C.

Quick Facts

Papers Indexed
6
h-Index
5
Open Access
Yes
Publisher
Elsevier
Country
Netherlands
Website
Visit